On Wednesday, Shares of Bank of America Corporation (NYSE:BAC), lost -0.18% to $16.74.
Bank of America Corporation, Chief Executive Officer Brian Moynihan will take part in the Bernstein Planned Decisions Conference on Wednesday, May 27 at 8 a.m. Eastern Time.
Bank of America Corporation, through its auxiliaries, provides banking and financial products and services for individual consumers, small and middle market businesses, institutional investors, large corporations, and governments worldwide.
Shares of Cablevision Systems Corporation (NYSE:CVC), inclined 18.02% to $24.69, during its last trading session, hitting its highest level, after the cable television provider had its rating upgraded to “buy” from “hold” by analysts at Pivotal Research Group.
The firm also raised the company’s price target to $31 from $18, suggesting a potential 22.5% enhance from the stock’s current trading price.
The stock is also being assisted recently by reports that the industry may be consolidating as French cable company Altice SA (ATC) is preparing to bid for Time Warner Cable (TWC), according to Reuters.
Cablevision Systems Corporation, together with its auxiliaries, owns and operates cable systems in the United States. The company operates through three segments: Cable, Lightpath, and Other.
At the end of Wednesday’s trade, Shares of Opko Health, Inc. (NYSE:OPK), gained 3.86% to $18.02, hitting its highest level.
OPKO Health, declared the online publication of a study entitled “A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort” in the journal European Urology. The study shows that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore® Test (Total PSA, Free PSA, Intact PSA and hK2) accurately identifies risk for aggressive prostate cancer preceding to prostate biopsy in a population of men referred for prostate biopsy based on Total PSA level and a Free PSA to Total PSA ratio.
“The Malmö study is the 12th peer-reviewed paper that demonstrated the accuracy of the 4K algorithm to accurately discriminate the presence of aggressive prostate cancer, even in a high risk population,” said David Okrongly, President of OPKO Diagnostics. “The results confirm that in a community-based clinical setting, the 4Kscore algorithm improves clinical decision-making for higher risk men with both elevated PSA and low Free PSA to Total PSA ratios, and can safely reduce at least 25% of unnecessary prostate biopsies.”
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
Finally, Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), ended its last trade with -0.10% gain, and closed at $19.29.
Momenta Pharmaceuticals, declared the pricing of its underwritten public offering of 7,250,000 shares of its common stock at the public offering price of $19.00 per share. Momenta has granted the underwriters an option to purchase up to an additional 1,087,500 shares of its common stock, exercisable for 30 days.
Goldman, Sachs & Co. and J.P. Morgan are acting as joint book-running managers for the offering. Stifel is acting as lead manager.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
